Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 8/20 | 0.65 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 3/20 | 0.50 |
| ▸ | LCK | P06239 | 2/20 | 0.50 |
| ▸ | TEK | Q02763 | 1/20 | 0.50 |
| ▸ | NEK7 | Q8TDX7 | 4/20 | 0.47 |
| ▸ | IGF1R | P08069 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27088013 | 0.89 | FLT3 (0.71) | FLT3RIPK1SRCLCKTEK | |
| SCHEMBL29998803 | 0.87 | EIF2AK3 (0.51) | FLT3RIPK1NEK7METAXL | |
| SCHEMBL25793334 | 0.87 | EIF2AK3 (0.51) | FLT3RIPK1NEK7METAXL | |
| SCHEMBL27088082 | 0.86 | FLT3 (0.52) | FLT3RIPK1SRCLCKTEK | |
| SCHEMBL29998505 | 0.86 | FLT3 (0.52) | FLT3RIPK1SRCLCKTEK | |
| SCHEMBL29999172 | 0.84 | ABL1 (0.49) | FLT3RIPK1SRCLCK | |
| SCHEMBL23966929 | 0.81 | NEK7 (0.64) | FLT3SRCNEK7 | |
| SCHEMBL29484486 | 0.81 | NEK7 (0.64) | FLT3SRCNEK7 | |
| SCHEMBL29998305 | 0.79 | FLT3 (0.58) | FLT3RIPK1SRCLCKTEK | |
| SCHEMBL23966781 | 0.79 | FLT3 (0.58) | FLT3RIPK1SRCLCKTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317758-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| EP-4320127-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022216680-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317758-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | FLT3 2113/4885RIPK1 51/4885SRC 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.